Highlights Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Delayed Nasdaq Other stock markets 09:36:06 2024-05-01 am EDT			5-day change	1st Jan Change
4.1 ^USD	+1.23%		-6.82%	-25.45%

Apr. 30	Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target	MT
Mar. 27	North American Morning Briefing : Stocks Edge -2-	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for ?Neldaleucel? as Nonproprietary Name for MT-601	Jan. 22	CI
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	Jan. 08	CI
Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study	Dec. 11	CI
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q3 Revenue $257.6M	Nov. 09	MT
Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse	23-09-11	CI
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q2 Revenue $762,658	23-08-14	MT
Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Marker Therapeutics Says Acute Myeloid Leukemia Treatment Candidate Granted Orphan Drug Designation in European Union	23-07-10	MT
Marker Therapeutics, Inc. Announces Zedenoleucel, Its Multi-Tumor-Associated Antigen-Specific T Cell Product Candidate, Mt-401	23-07-10	CI
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells After Hypomethylating Agent Administration	23-06-26	CI
Cell Ready, LLC completed the acquisition of Certain Cell Manufacturing Assets of Marker Therapeutics, Inc.	23-06-25	CI
Marker Therapeutics, Inc. Reports Pre-Clinical Data of Its MT-601 multiTAA-Specific T Cell Product Candidate in Lymphoma Cells	23-05-31	CI
Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Marker Therapeutics, Inc. Announces Comprehensive Non-Dilutive Agreement with CellReady	23-05-01	CI
Cell Ready, LLC entered into a purchase agreement to acquire Certain Cell Manufacturing Assets of Marker Therapeutics, Inc. for $19 million.	23-04-30	CI
Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Marker Therapeutics Announces U.S. Food and Drug Administration Clearance of IND for MT-601, Its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer	22-11-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Highlights

Filters